Reports & White Papers

View the latest Biosimilars Council reports and white papers for detailed information about what biosimilars are, how they work and how they generate savings for patients and the health care system.

2024 AAM generic & Biosimilar Savings Report
September 5, 2024
Report

2024 U.S. Generic & Biosimilar Medicines Savings Report

December 18, 2023
Report

2023 U.S. Generic and Biosimilar Savings Report: Biosimilars Deliver on Their Promise

August 14, 2023
Report

Semglee Launch Tracking

September 21, 2022
Report

2022 U.S. Generic and Biosimilar Savings Report: Biosimilars Deliver on Their Promise

October 12, 2021
Report

2021 U.S. Generic and Biosimilar Medicines Savings Report: The Promise of Biosimilars

February 22, 2021
Whitepapers

AAM Report: Securing Sustainable Markets

twitter chat
September 28, 2020
Whitepapers

Global Roadmap for Tailored Clinical Biosimilar Development: Instrumental for Sustainable Access to Biologics

biosimilars in the pharmacy
July 16, 2020
Whitepapers

Biosimilars In The Pharmacy

europe's biosimilars market
June 3, 2020
Whitepapers

Lessons for the United States on Europe’s Biosimilar Experience

barriers to biosimilar adoption
September 9, 2019
Whitepapers

Biosimilars Uptake Failure

June 25, 2019
Whitepapers

Patent Abuse Blocks Access to Biosimilars for Patients

May 13, 2019
Council Resource
Whitepapers

Insulin Biosimilars: Ensuring Access for America’s Diabetes Patients

The Biosimilars Council - 2018 Access and Savings Report Cover Zoomed In
July 25, 2018
Report

2018 Generic Drug Access & Savings in the U.S.

The Biosimilars Council - Breaking Through on Biosimilars Whitepaper
May 30, 2018
Report
Whitepapers

White Paper: Breaking Through on Biosimilars

Patient Access Report: Biosimilars in the United States
April 30, 2018
Report

Patient Access Report: Biosimilars in the U.S.

July 6, 2017
Report

2017 Generic Drug Access and Savings in the U.S. Report

MENU